# A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

> **NCT00587457** · PHASE1 · TERMINATED · sponsor: **MedImmune LLC** · enrollment: 11 (actual)

## Conditions studied

- Leukemia, Lymphoma, Chronic Lymphocytic
- Leukemia, Prolymphocytic Leukemia, Small
- Lymphocytic Lymphoma, Moxetumomab Pasudotox

## Interventions

- **DRUG:** CAT-8015 5 mcg/kg
- **DRUG:** CAT-8015 10 mcg/kg
- **DRUG:** CAT-8015 20 mcg/kg

## Key facts

- **NCT ID:** NCT00587457
- **Lead sponsor:** MedImmune LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03-07
- **Primary completion:** 2008-04-07
- **Final completion:** 2008-04-07
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The study is terminated early due to unavailability of investigational product.
- **Last updated:** 2017-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00587457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00587457, "A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00587457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*